Safety considerations of the use of second generation antipsychotics in the treatment of major depression: Extrapyramidal and metabolic side effects

Current Drug Safety

Volumn 5, Issue 3, 2010, Pages 263-266

  DeBattista, Charles ^a   DeBattista, Kristina ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti psychotics; Drug treatment; Major depression; Toxicity

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; OLANZAPINE; PAROXETINE; QUETIAPINE; SEROTONIN 2A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DOPAMINERGIC TRANSMISSION; DRUG SAFETY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCORTISOLISM; HYPERGLYCEMIA; LIPID METABOLISM; MAJOR DEPRESSION; MANIA; METABOLIC DISORDER; MONOTHERAPY; NIGRONEOSTRIATAL SYSTEM; OBESITY; PARKINSONISM; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TRANQUILIZING ACTIVITY; TREATMENT DURATION; TREMOR; WEIGHT; WEIGHT GAIN; CHEMICALLY INDUCED; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; RISK FACTOR; UNITED STATES;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; HUMANS; METABOLIC DISEASES; RISK FACTORS; UNITED STATES;

EID: 77954679900     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488610791698325     Document Type: Article

References (50)

1. Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep 2008; 10(6): 481-6.
2. Musenga A, Saracino MA, Sani G, Raggi MA. Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. Curr Med Chem 2009; 16(12): 1463-81.
3. DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009; 23(5): 369-77.
4. Rush AJ, Trivedi MH, Wisniewski SR. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905-17.
5. Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry 2007; 68(Suppl 10): 8-10.
6. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007; 9(6): 449-59.
7. nd ed. Cambridge: Cambridge University Press 2000.
8. Kaneko M, Mashiko H, Yagiuchi T, Ohsuka N, Kumashiro H. 5HT2 receptor-mediated function in depressed patients: investigation by measuring 5HT-induced shape change of blood platelets. Japan J Psychiatry Neurol 1992; 46(1): 169-74.
9. Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN. 5HT2 receptor changes in major depression. Biol Psychiatry 1990; 27(5): 489-96.
10. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol 2009; 88(1): 17-31.
11. Baca E, Azanza JR, Giner J, et al. Ziprasidone: from pharmacology to the clinical practice. One year of experience. Actas Esp Psiquiatr 2005; 33(5): 311-24.
12. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second- generation antipsychotic drugs: a validity of the serotonin- dopamine hypothesis. Prog Brain Res 2008; 172: 199-212.
13. Ballas C, Yang C, Reardon J, Ballas P, Baldassano C. Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004; 4(2): 179-86.
14. Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs 2007; 16(6): 771-5.
15. Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symp- toms and their management. Expert Opin Pharmacother 2008; 9(9): 1451-62.
16. Correll CU, Schenk EM. Tardive dyskinesia and new antipsycho- tics. Curr Opin Psychiatry 2008; 21(2): 151-6.
17. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21(5): 589-98.
18. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13(1): 27-35.
19. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68(Suppl 4): 8-13.
20. Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984; 25(2): 135-8.
21. Yassa R, Schwartz G. Depression as a predictor in the development of tardive dyskinesia. Biol Psychiatry 1984; 19(3): 441-4.
22. Dinan TG, Kohen D. Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Br J Psychiatry 1989; 155: 55-7.
23. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006; 67(1): 107-13.
24. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14(4): 197-206.
25. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo- controlled study. J Clin Psychopharmacol 2008; 28(2): 156-65.
26. Nelson JC, Mankoski R, Baker RA, et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 120(1-3): 133-40.
27. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double- blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68(2): 224-36.
28. Trivedi MH, Thase ME, Osuntokun O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment- resistant depression. J Clin Psychiatry 2009; 70(3): 387-96.
29. Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009; 14(6): 299-313.
30. Yassa R, Camille Y, Belzile L. Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. J Clin Psychopharmacol 1987; 7(4): 243-6.
31. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146(3): 399-400.
32. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57(10): 449-54.
33. Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 1992; 53(11): 401-6.
34. Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor- induced akathisia. J Am Pharm Assoc (2003), 2009; 49(2): e28-36; quiz e37-8.
35. Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26(3): 142-5.
36. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17(5): 377-89.
37. Ozalp E, Soygur H, Cankurtaran ES, et al. Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(7): 1337-9.
38. Mamo DC, Sweet RA, Mulsant BH, et al. Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients. Am J Geriatr Psychiatry 2000; 8(3): 226-31.
39. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009; 4(3): 229-37.
40. rd ed., Montvale, NJ: Physician's Desk Reference Inc 2009.
41. Corya SA, Perlis RH, Keck PE Jr, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006; 67(5): 798-806.
42. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70(4): 540-9.
43. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70(4): 526-39.
44. Rihmer Z, Purebl G, Faludi G, Halmy L. Association of obesity and depression. Neuropsychopharmacol Hung 2008; 10(4): 183-9.
45. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003; 54(3): 317-29.
46. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003; 64(Suppl 8): 22-9.
47. Lustman PJ, Griffith LS, Freedland KE, Clouse RE. The course of major depression in diabetes. Gen Hosp Psychiatry 1997; 19(2): 138-43.
48. Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag 2007; 3(6): 833-44.
49. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007; 13(7 Suppl): S170-7.
50. Newcomer JW, Lieberman JA. Comparing safety and tolerability of antipsychotic treatment. J Clin Psychiatry 2007; 68(3): e07.